FILTER
LATEST INTERVIEWS
James Greenwood
PRESIDENT & CEO, BIOTECHNOLOGY INNOVATION ORGANIZATION
The Biotechnology Innovation Organization (BIO) represents biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations.
Enrique Flaiban
GENERAL MANAGER, PETROCUYO
Petrocuyo is an Argentinian company that resulted from the merger between Petroquímica Cuyo and Petroken.
Doug Giordano
SENIOR VP, BUSINESS DEVELOPMENT, PFIZER
A look at the latest trends in business development from a global pharma powerhouse.
Scott Baker
CEO, TORNADO SPECTRAL SYSTEMS
Tornado Spectral Systems is a Toronto-based startup that designs, manufactures and sells dispersive optical spectrometers and systems for Raman spectroscopy.
Brian Maher
PRESIDENT AND CEO, PPX MINING
PPX Mining is a Canadian-based exploration and development company with assets in northern Peru.
Duane Nelson
CEO AND DIRECTOR, ENVIROLEACH
EnviroLeach offers gold miners an alternative for cyanide and explores recycling techniques
Denver Dreyer
CEO, WORLEYPARSONS RSA
WorleyParsons is an engineering company that provides project delivery and consulting services to the resources and energy sectors, and complex process industries.
Debbie Hart
PRESIDENT AND CEO, BIONJ
Founded in 1994, BioNJ’s mission is to enhance the climate for the life sciences industry in the state.
Arda Ural
PHD PARTNER & OPERATIONAL TRANSACTION SERVICES LIFE SCIENCES LEADER - TRANSACTION ADVISORY SERVICES, ERNST AND YOUNG (EY)
EY is a multinational professional services firm headquartered in London, United Kingdom.
Annette Grimaldi
MANAGING DIRECTOR, LIFE SCIENCES INVESTMENT BANKING, BMO CAPITAL MARKETS
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
